Nifty
Sensex
:
:
22405.60
73872.29
27.20 (0.12%)
66.14 (0.09%)

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 524715 | NSE: SUNPHARMA

1552.10
04-Mar-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1550.55
  •  1569.10
  •  1548.90
  •  1550.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2298105
  •  35876.00
  •  1587.80
  •  922.45

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 372,436.77
  • 41.82
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 366,702.66
  • 0.74%
  • 5.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.14%
  • 5.41%
  • FII
  • DII
  • Others
  • 17.08%
  • 18.06%
  • 2.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.56
  • 8.59
  • 9.42

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 12.81
  • 6.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.49
  • 26.15
  • 42.97

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.03
  • 34.53
  • 38.18

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.77
  • 3.61
  • 4.28

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.43
  • 17.76
  • 19.65

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
12,380.70
11,240.97
10.14%
12,192.41
10,952.28
11.32%
11,940.84
10,761.76
10.96%
10,930.67
9,446.76
15.71%
Expenses
9,028.43
8,237.25
9.60%
9,013.03
7,995.73
12.72%
8,611.11
8,023.04
7.33%
8,128.54
7,267.41
11.85%
EBITDA
3,352.27
3,003.72
11.60%
3,179.38
2,956.55
7.54%
3,329.73
2,738.72
21.58%
2,802.13
2,179.35
28.58%
EBIDTM
27.08%
26.72%
26.08%
26.99%
27.89%
25.45%
25.64%
23.07%
Other Income
374.76
173.88
115.53%
293.61
85.22
244.53%
206.48
147.81
39.69%
373.28
274.61
35.93%
Interest
34.73
46.18
-24.79%
49.29
19.39
154.20%
80.88
13.69
490.80%
92.74
37.34
148.37%
Depreciation
622.14
659.95
-5.73%
632.82
609.95
3.75%
651.32
588.00
10.77%
671.53
556.47
20.68%
PBT
3,000.35
2,471.47
21.40%
2,790.88
2,412.43
15.69%
2,481.14
2,284.84
8.59%
2,239.69
-2,075.60
-
Tax
432.32
283.43
52.53%
390.10
152.26
156.21%
468.10
188.99
147.69%
222.91
146.76
51.89%
PAT
2,568.03
2,188.04
17.37%
2,400.78
2,260.17
6.22%
2,013.04
2,095.85
-3.95%
2,016.78
-2,222.36
-
PATM
20.74%
19.46%
19.69%
20.64%
16.86%
19.48%
18.45%
-23.53%
EPS
10.52
9.03
16.50%
9.90
9.43
4.98%
8.43
8.59
-1.86%
8.27
-9.49
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
47,444.62
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
Net Sales Growth
11.89%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
 
Cost Of Goods Sold
10,532.42
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
Gross Profit
36,912.20
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
GP Margin
77.80%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
Total Expenditure
34,781.11
32,424.22
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
Power & Fuel Cost
-
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
% Of Sales
-
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
Employee Cost
-
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
% Of Sales
-
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
Manufacturing Exp.
-
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
% Of Sales
-
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
General & Admin Exp.
-
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
% Of Sales
-
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
Selling & Distn. Exp.
-
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
% Of Sales
-
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
Miscellaneous Exp.
-
1,216.85
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
1,394.78
% Of Sales
-
2.77%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
EBITDA
12,663.51
11,461.46
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
EBITDA Margin
26.69%
26.12%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
Other Income
1,248.13
819.85
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
Interest
257.64
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
Depreciation
2,577.81
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
PBT
10,512.06
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
Tax
1,513.43
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
Tax Rate
14.40%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
PAT
8,998.63
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
PAT before Minority Interest
8,970.71
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
Minority Interest
-27.92
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
PAT Margin
18.97%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
PAT Growth
108.22%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
 
EPS
37.51
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
Total Reserves
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
Non-Current Liabilities
-1,643.12
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
Secured Loans
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
Unsecured Loans
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
Long Term Provisions
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
Current Liabilities
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
Trade Payables
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
Other Current Liabilities
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
Short Term Borrowings
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
Short Term Provisions
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
Total Liabilities
77,578.73
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
Net Block
24,420.12
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
Gross Block
43,454.63
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
Accumulated Depreciation
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
Non Current Assets
37,696.01
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
Capital Work in Progress
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
Non Current Investment
5,457.48
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
Long Term Loans & Adv.
2,752.12
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
Other Non Current Assets
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
Current Assets
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
Current Investments
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
Inventories
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
Sundry Debtors
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
Cash & Bank
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
Other Current Assets
2,767.48
775.01
1,319.11
1,541.48
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
3,774.42
Short Term Loans & Adv.
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
Net Current Assets
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
Total Assets
77,557.95
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
PBT
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
Adjustment
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
Changes in Working Capital
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
Cash after chg. in Working capital
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
Net Fixed Assets
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
Net Investments
2,932.47
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
Others
-10,302.18
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
Cash from Financing Activity
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
Net Cash Inflow / Outflow
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
Opening Cash & Equivalents
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
Closing Cash & Equivalent
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
ROA
11.85%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
ROE
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
ROCE
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
Fixed Asset Turnover
1.81
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
Receivable days
53.89
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
Inventory Days
47.78
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
Payable days
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
Cash Conversion Cycle
-72.43
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
Total Debt/Equity
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
Interest Cover
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67

News Update:


  • Sun Pharmaceutical to acquire 16.33% stake in Surgimatix
    21st Feb 2024, 12:00 PM

    The cost of acquisition is around $3.05 million

    Read More
  • Sun Pharma included in S&P Global Sustainability Yearbook 2024
    12th Feb 2024, 11:42 AM

    This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance principles through focused initiatives across its businesses

    Read More
  • Sun Pharmaceutical Industries’ arm incorporates wholly-owned subsidiary
    6th Feb 2024, 10:15 AM

    Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA

    Read More
  • Sun Pharmaceutical Industries reports 17% rise in Q3 consolidated net profit
    31st Jan 2024, 17:17 PM

    Total consolidated income of the company increased by 10.65% at Rs 12630.90 crore for Q3FY24

    Read More
  • Sun Pharmaceutical to acquire remaining stake in Taro Pharmaceutical Industries
    18th Jan 2024, 14:14 PM

    Sun Pharmaceutical will acquire 8,086,818 shares constituting 21.52% of the total outstanding shares of Taro for a cash consideration of $43 per share amounting to Rs 2,891.76 crore

    Read More
  • Sun Pharmaceutical Industries inks pact with Bayer
    17th Jan 2024, 14:41 PM

    Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa

    Read More
  • Sun Pharmaceutical Industries acquires 100% stake in Libra Merger
    3rd Jan 2024, 11:56 AM

    The objective of acquisition is to facilitate consolidation of business in Israel

    Read More
  • Sun Pharmaceutical Industries to acquire 16.7% shares in Lyndra Therapeutics, Inc
    19th Dec 2023, 09:58 AM

    This strategic investment is to support development of innovative pharmaceutical delivery technologies and get access to the technology for certain molecules and territories

    Read More
  • Sun Pharma’s arm recalls 96,192 bottles of Liothyronine Sodium Tablets in US
    18th Dec 2023, 14:23 PM

    Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot that was produced at the drugmaker’s Dadra-based facility

    Read More
  • Sun Pharma's specialty product Ilumetri included in China's national reimbursement drug list
    13th Dec 2023, 14:39 PM

    Ilumetri was approved for marketing in China in May 2023

    Read More
  • Sun Pharma’s arm enters into licensing agreement with Aclaris Therapeutics, Inc.
    6th Dec 2023, 09:19 AM

    The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.